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See Editorial, pages 996–999IntroductionBackground & Aims:We conducted an open-label phase 2 study
to assess the efﬁcacy and safety of the oral nucleotide polymerase
inhibitor sofosbuvir in combination with ribavirin in patients of
Egyptian ancestry, chronically infected with genotype 4 hepatitis
C virus (HCV).
Methods: Treatment-naive and previously treated patients with
genotype 4 HCV were randomly allocated in a 1:1 ratio to receive
sofosbuvir 400 mg and weight-based ribavirin, for 12 or
24 weeks. The primary efﬁcacy endpoint was the proportion of
patients with sustained virologic response (HCV RNA
<25 IU/ml) 12 weeks after cessation of therapy (SVR12).
Results: Thirty treatment-naive and thirty previously treated
patients were enrolled and treated for 12 weeks (n = 31) or
24 weeks (n = 29). Overall, 23% of patients had cirrhosis and
38% had diabetes. 14% of treatment-naive patients were interfer-
on ineligible and 63% of treatment-experienced patients had
prior non-response. SVR12 was achieved by 68% of patients
(95% CI, 49–83%) in the 12-week group, and by 93% of patients
(95% CI, 77–99%) in the 24-week group. The most common
adverse events were headache, insomnia, and fatigue. No patient
discontinued treatment due to an adverse event.
Conclusions: The ﬁndings from the present study suggest that
24 weeks of sofosbuvir plus ribavirin is an efﬁcacious and well
tolerated treatment in patients with HCV genotype 4 infection.
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intervals; ABT-450/r, ABT-450 with ritonavir.The genotype 4 strain of the hepatitis C virus (HCV) accounts for
approximately 20% of all cases of chronic HCV infection world-
wide [1]. In Egypt, where an estimated 15% of the population
may have chronic hepatitis C, over 90% of the infections have
been reported to be HCV genotype 4 [1–4]. The spread of chronic
HCV infection in Egypt is thought to be largely due to needle
re-use during mass-treatment programs for schistosomiasis dur-
ing the late 1950s through the early 1980s [5,6]. Unfortunately,
transmission continues to occur, primarily through iatrogenic
sources, such as blood transfusions, injections, and dental care
[1,2]. HCV genotype 4 is also the most common genotype in other
parts of the Middle East and Africa, and its prevalence is increas-
ing in Europe and parts of North America where it has been asso-
ciated with immigration and intravenous drug use [1,2].
Until recently, the standard of care for genotype 4 HCV in the
United States and Europe has been pegylated interferon
(PegIFNa) with ribavirin (RBV) for 24 to 48 weeks, depending
on virologic response [1]. Treatment-naive patients receiving this
regimen have sustained virologic response (SVR) rates of 43% to
70% [1,2,7]. New regimens involving direct-acting antiviral agents
(DAAs) have recently been approved for the treatment of geno-
type 4 HCV. These regimens appear to offer improved rates of
SVR in treatment-naive and previously treated patients with
genotype 4 HCV; however, few patients have received these regi-
mens and data concerning efﬁcacy and safety are sparse [8].
One of the newly approved DAAs indicated for the treatment of
genotype 4 HCV is sofosbuvir (Gilead Sciences, Inc., Foster City,
California, USA), an oral, HCV-speciﬁc NS5B nucleotide poly-
merase inhibitor with demonstrated clinical efﬁcacy in patients
with genotype 1 to 6 HCV [9,10]. In a phase 3 trial, an SVR was
observed in 27 of 28 treatment-naive patients (96%) with geno-
type 4 HCV receiving 12 weeks of sofosbuvir in combination with
PegIFNa and RBV [9]. The current hepatitis C treatment guidelines
for treatment of genotype 4 HCV issued by the American
Association for the Study of Liver Diseases (AASLD), European
Association for the Study of the Liver (EASL), and World Health
Organization (WHO) include sofosbuvir administered in15 vol. 62 j 1040–1046
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combination with PegIFNa and RBV for 12 weeks or an
interferon-free regimen of sofosbuvir in combination with RBV
for 24 weeks [11–13].
The development of an interferon-free regimen for genotype 4
HCV infection has the potential to signiﬁcantly impact the inci-
dence, prevalence, and overall burden of HCV, particularly in
Egypt, where the prevalence of genotype 4 HCV is so high. For
many, treatment with interferon-containing regimen is impossi-
ble, undesirable, or insufﬁciently efﬁcacious. Elimination of inter-
feron from the treatment regimen may reduce the required
frequency of safety monitoring, and facilitate treatment of chron-
ic hepatitis C in rural areas, which in Egypt have higher preva-
lence rates than the national average [4]. The large Egyptian
immigrant population in the United States has afforded the
opportunity to perform a pilot study of an interferon-free regi-
men containing sofosbuvir plus RBV in treatment-naive and




Patients were screened and enrolled in this phase 2, open-label study at a single
center in the United States between October 2012 and March 2013
(ClinicalTrials.gov Identiﬁer NCT01713283). To be eligible, patients had to be born
in Egypt to two parents of Egyptian ancestry. Patients were required to be at least
18 years of age with bodymass indexP18 kg/m2 and had chronic genotype 4 HCV
infection with a serum HCV RNA level P104 log IU/ml. Up to 20% of enrolled
patients may have had compensated cirrhosis at screening. The presence of cirrho-
sis was determined on the basis of a liver biopsy specimen showing evidence of
cirrhosis or a Fibrotest (Laboratory Corporation of America Holdings,
Burlington, North Carolina, USA) score >0.75 plus an aspartate aminotransferase:-
platelet ratio index (APRI) >2 during screening. Laboratory requirements included
alanine and aspartate aminotransferase610 times the upper limit of normal (ULN),
direct bilirubin 61.5 times ULN, hemoglobin P12 g/dl for men and P11 g/dl for
women, and creatinine clearanceP60 ml/min (Cockcroft-Gault). Consistent with
the inclusion of patients with cirrhosis, no minimum neutrophil count was
required and patients with platelets >50,000/ll were eligible for participation.
Patients with hepatitis B or HIV were excluded. Patients could be either
treatment-naive or treatment-experienced; prior treatment with an anti-HCV
direct-acting antiviral was exclusionary.
Hepatitis C virus GT 4 genotyping at screening was determined using the
VERSANT HCV Genotype 2.0 Assay (LiPA) (Siemens, Erlangen, Germany) or by
population sequencing of a short fragment of the coding region of the NS5B gene
(Janssen Diagnostics, Beerse, Belgium), subsequently conﬁrmed by population or
deep sequencing (DDL Diagnostic Laboratory, Rijswijk, The Netherlands). IL28B
genotype was determined by means of polymerase chain-reaction ampliﬁcation
and sequencing of the rs12979860 single-nucleotide polymorphism.
The study was conducted in accordance with the guidelines of Good Clinical
Practice and was approved by an Independent Review Board. All patients provid-
ed written informed consent.
Study design
Patients were randomly assigned in a 1:1 ratio to receive treatment with sofos-
buvir plus RBV for 12 or 24 weeks. Randomization was stratiﬁed by prior treat-
ment experience and cirrhosis status via a computer-generated random
allocation sequence prepared by the sponsor. Sofosbuvir was given orally at a
dose of 400 mg once daily, and weight-based RBV was given orally as a divided
weight-based daily dose (1000 mg for patients with body weight <75 kg and
1200 mg with body weight P75 mg). RBV dose adjustment was permitted
according to prescribing instructions. Use of growth factors was not permitted.
Efﬁcacy assessments
Serum HCV RNA was measured using the COBAS TaqMan HCV Test v2.0 (Roche
Molecular Systems, Pleasanton, California, USA; lower limit of quantitation
(LLOQ) of 25 IU/ml) at baseline, all subsequent study visits during treatment,Journal of Hepatology 2015and post-treatment weeks 4, 12, and 24. Patients with conﬁrmed HCV RNA
<LLOQ at the end of treatment and post-treatment visits continued to the
subsequent post-treatment visits, unless conﬁrmed virologic relapse occurred.
On-treatment virologic failure was deﬁned as: breakthrough, i.e. conﬁrmed
HCV RNA PLLOQ after having previously had HCV RNA <LLOQ while
on-treatment; rebound, i.e. conﬁrmed >1-log10 IU/ml increase in HCV RNA from
nadir while on-treatment; or, non-response, i.e. HCV RNA persistently PLLOQ
through 8 weeks of treatment. Relapse was deﬁned as conﬁrmed HCV RNA
PLLOQ during the post-treatment period having achieved HCV RNA <LLOQ at
the end of treatment.
Safety assessments
Safety was evaluated by assessment of clinical laboratory tests, physical examina-
tion, vital sign measurements, and documentation of adverse events. Safety data
were collected from the ﬁrst dose of study medication through 30 days after the
last dose.
HCV resistance testing
For all patients who did not achieve SVR12, deep sequencing of the HCV NS5B
gene, with a 1% assay cut-off, was performed at baseline and at the ﬁrst viro-
logic failure time point, if a serum sample was available and HCV RNA was
>1000 IU/ml. The HCV NS5B coding region was ampliﬁed, and population- or
deep-sequenced by DDL Diagnostic Laboratory (Rijswijk, The Netherlands) or
Selah Genomics (Greenville, South Carolina, USA). Standard reverse transcrip-
tion polymerase chain-reaction technology was used for ampliﬁcation followed
by deep sequencing of the polymerase chain-reaction product at baseline and
virologic failure time points. Amino-acid substitutions in the NS5B coding
region in the samples collected at virologic failure were compared with the
respective baseline sequence for each patient. The availability of short frag-
ment population sequence of the NS5B coding region from subtype determina-
tion allowed for baseline characterization of the S282 residue from all patients
that achieved SVR12. NS5B nucleoside inhibitor (NI) RAVs were deﬁned as the
following substitutions at the following positions: S96T, N142T, L159F,
S282any, M289I/L/V, L320F, and V321A.
Pharmacokinetics
Single blood samples were collected at baseline and each subsequent treatment
visit for pharmacokinetic analysis. Plasma concentrations of sofosbuvir and its
predominant circulating nucleoside metabolite (GS-331007) were determined
using fully-validated high-performance liquid chromatography/tandem mass
spectrometry bioanalytical methods (QPS, LLC, Newark, Delaware, USA). Plasma
concentrations of sofosbuvir and GS-331007 were used to estimate pharmacoki-
netic exposure parameters (area under the concentration-time curve over the
dosing interval [AUCtau] and the maximum concentration [Cmax]) for sofosbuvir
and GS-331007 using population pharmacokinetics models previously developed
with data from earlier phase 2/3 studies [14]. GS-331007 and sofosbuvir expo-
sures observed in the patient population in this study were compared to expo-
sures obtained in the phase 2/3 study population generated using the same
population PK models.
Statistical assessments
The primary efﬁcacy endpoint was the proportion of all randomized patients who
achieved a sustained virologic response 12 weeks after the end of treatment
(SVR12). Secondary efﬁcacy endpoints included SVR4 and SVR24, on-treatment
virologic failure, and virologic relapse after the end of treatment. In the primary
efﬁcacy analysis, SVR12 rates were calculated for each treatment group, along
with 2-sided 95% conﬁdence intervals (CIs) based on the Clopper-Pearson exact
method. No statistical hypothesis testing was performed.Results
Patients
Of the 80 patients screened, 60 patients were enrolled and com-
pleted treatment with sofosbuvir plus RBV for 12 weeks (n = 31)vol. 62 j 1040–1046 1041
80 patients screened
60 patients randomly assigned
20 patients were not randomized
17 did not meet eligibility criteria
2 were outside of visit window
1 enrollment closed
29 patients assigned to
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Fig. 1. Patient disposition. FU, follow-up; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir.
Research Articleor 24 weeks (n = 29) (Fig. 1). The 12- and 24-week treatment
groups were balanced for demographic and baseline characteris-
tics, except that the 12-week group had a greater proportion of
patients with HCV genotype 4a (Table 1). The mean age of
enrolled patients was 54 years, 68% were men, 80% had genotype
4a infection, 83% had IL28B non-CC genotype, 33% had a body
mass index P30 kg/m2, 23% had cirrhosis, 38% had diabetes,
and all but two had platelet counts >100,000/ll. Of the 14
patients with protocol-deﬁned cirrhosis, 11 had a historical or
screening liver biopsy specimen showing evidence of cirrhosis;
the other three were judged to have cirrhosis on the basis of hav-
ing a Fibrotest score >0.75 plus an APRI score >2. Among
treatment-naive patients, 14% were interferon ineligible. Among
treatment-experienced patients, the most common reason for
prior HCV treatment failure was non-response, occurring in 63%
of patients.
Efﬁcacy
HCV RNA levels declined rapidly upon initiation of treatment,
from a mean of 5.98 log10 IU/ml at baseline to 1.81 log10 IU/ml
in the 12-week group and from 5.97 log10 IU/ml to
1.74 log10 IU/ml in the 24-week group after one week of treat-
ment. All patients except one in the 12-week group had HCV
RNA below the lower limit of quantiﬁcation by week 4.
SVR12 was achieved by 21 of the 31 patients (68%; 95%, CI 49–
83%) receiving 12 weeks of treatment, and by 27 of the 29 patients
(93%; 95%, CI 77–99%) receiving 24 weeks of treatment (Table 2).
In general, differences in favor of 24 weeks of treatment were
observed for most patient subgroups, although the numbers of
patients within each subgroupwere often small. SVR12 rates were
numerically higher in patients younger than 65 years and in
patients with body mass index P30 kg/m2 in both the 12 and1042 Journal of Hepatology 201524-week treatment groups, while numeric differences were seen
in the 12-week but not the 24-week group for those with cirrho-
sis, high baseline viral load, or IL28B non-CC genotype. The SVR12
rates among treatment-naive patients were higher (79% in the
12-week group and 100% in the 24-week group) than among
treatment-experienced patients (Table 2). The rates of SVR12 in
patients with genotype 4a vs. non-4a infection were similar:
81% vs. 75%. RBV dose reduction did not appear to have an effect
on SVR12 rate: of the 11 patients who received RBV dose reduc-
tion during treatment, 9 (82%) achieved SVR12.
In total, 10 patients in the 12-week group and 2 patients in the
24-week group had virologic failure. Ten of the 12 patients
relapsed by week 4 post-treatment and one patient in the
24-week group relapsed between week 4 and week 12
post-treatment. One treatment-naive patient in the 12-week
group had on-treatment virologic failure (breakthrough); this
64-year-old female patient had genotype 4l HCV, cirrhosis, and
the IL28B CT genotype. She completed 12 weeks of treatment
and achieved HCV RNA <LLOQ by week 8, but had quantiﬁable
HCV RNA at treatment weeks 10 and 12. All patients with
SVR12 who returned for the 24-week post-treatment visit
achieved SVR24; two were lost to follow-up.
Viral sequencing
Viral isolates from all 60 patients enrolled had sequencing
performed of the region covering the sofosbuvir
resistance-associated variant site S282. No variants in this region
were observed at baseline in the 49 patients with population
sequencing for this region or in the 11 with full NS5B deep
sequencing data. No S282T variants were observed at the virolog-
ic failure time points in the 12 patients who did not achieve
SVR12, including the patient who had viral breakthroughvol. 62 j 1040–1046
Table 1. Demographics and baseline characteristics.
Characteristic SOF + RBV
12 week (n = 31)
SOF + RBV
24 week (n = 29)
Mean age, yr (range) 53 (26-72) 55 (27-75)
Male, n (%) 22 (71) 19 (66)
Mean body mass index, 
kg/m2 (range)
28.6 (21.3-34.5) 30.2 (19.9-42.3)
HCV genotype, n (%)
4a 28 (90) 20 (69)
4l 1 (3) 1 (3)
4m 0 1 (3)
4n 1 (3) 2 (7)
4o 1 (3) 5 (17)
IL28B genotype, n (%)
CC 4 (13) 6 (21)
CT 20 (65) 19 (66)
TT 7 (23) 4 (14)
Mean baseline HCV RNA, 
log10 IU/ml (range)
6.0 (4.7-7.0) 6.0 (4.3-7.2)
Cirrhosis, n (%) 7 (23) 7 (24)
Treatment naïve, n (%) 14 (45) 14 (48)
Interferon ineligible 1 (7) 3 (21)
Treatment experienced, 
n (%)
17 (55) 15 (52)
Prior non response 10 (59) 10 (67)
Prior relapse/
breakthrough
5 (29) 1 (7)
Interferon intolerant 2 (12) 2 (13)
Unknown response 0 2 (13)
Diabetes mellitus 13 (42) 10 (34)
HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir.
Table 2. SVR12 rates overall and by patient subgroup.
Patients, n/N 
(%; 95% CI)
SOF + RBV 12 week 
(n = 31)
SOF + RBV 24 week
(n = 29)
Overall 21/31 (68%; 49-83) 27/29 (93%: 77-99)
Age
<65 yr 19/27 (70%; 50-86) 20/20 (100%; 83-100)
≥65 yr 2/4 (50%; 7-93) 7/9 (78%; 40-97)
Sex
Male 13/22 (59%; 36-79) 17/19 (89%; 67-99)
Female 8/9 (89%; 52-100) 10/10 (100%; 69-100)
Baseline body mass index
<30 kg/m2 15/23 (65%; 43-84) 15/17 (88%; 64-99)
≥30 kg/m2 6/8 (75%; 35-97) 12/12 (100%; 74-100)
Baseline HCV RNA, IU/ml
<800,000 10/11 (91%; 59-100) 14/15 (93%; 68-100)
≥800,000 11/20 (55%; 32-77) 13/14 (93%; 66-100)
Cirrhosis status
Yes 3/7 (43%; 10-82) 7/7 (100%; 59-100)
No 18/24 (75%; 53-90) 20/22 (91%; 71-99)
HCV genotype
4a 19/28 (68%; 48-84) 20/20 (100%; 83-100)
Other (4l, 4m, 
4n, 4o)
2/3 (67%; 9-99) 7/9 (78%; 40-97)
IL28B genotype
CC 4/4 (100%; 40-100) 6/6 (100%; 54-100)
Non-CC 17/27 (63%; 42-81) 21/23 (91%; 72-99)
Treatment history
Naive 11/14 (79%; 49-95) 14/14 (100%; 77-100)
Previously 
treated
10/17 (59%; 33-82) 13/15 (87%; 60-98)*
Non-response 5/10 (50%; 19-81) 9/10 (90%; 55-100)
Relapse/
breakthrough
4/5 (80%; 28-99) 1/1 (100%; 3-100)
IFN-intolerant 1/2 (50%; 1-99) 1/2 (50%; 1-99)
⁄Prior response type was not known for two previously treated patients in the
24-week group.
JOURNAL OF HEPATOLOGYon-treatment. One patient who relapsed harbored a viral popula-
tion with a low level (1.6%) of the S282G variant; the clinical sig-
niﬁcance of this variant is unclear as this mutant does not
replicate in vitro. No other sofosbuvir treatment-emergent vari-
ants were observed in the 11 samples successfully
deep-sequenced.
Pharmacokinetics
GS-331007 and sofosbuvir population pharmacokinetic
model-derived exposure parameters AUCtau and Cmax were gen-
erated for all patients with measureable plasma concentrations
of GS-331007 or sofosbuvir. Mean exposure of GS-331007, the
renally eliminated metabolite of sofosbuvir, was moderately
higher (AUCtau 46%, Cmax 42%) in this study population than in
HCV-infected patients in earlier phase 2/3 studies, even though
CLcr values were comparable in the two populations [14]. The
mechanism for this modest increase is unknown. The increased
GS-331007 exposure was not clinically relevant as the range of
exposures observed in the Egyptian population was comparable
to that observed in previous studies in which there had been
no exposure-related toxicities. Mean exposure of sofosbuvir
was comparable in the two populations. No clinically relevant
effects of age, sex, body mass index, creatinine clearance, or cir-
rhosis on GS-331007 or sofosbuvir exposure were observed,
which is consistent with ﬁndings from previous studies. No
clinically relevant differences in GS-331007 or sofosbuvirJournal of Hepatology 2015exposure were observed for study patients who received 12 vs.
24 weeks of sofosbuvir plus RBV, or in treatment-naive vs.
treatment-experienced patients, or in those who achieved
SVR12 vs. those with virologic failure.
Safety
Treatment-emergent adverse events, which were reported in 28
patients (90%) in the 12-week group and 29 (100%) in the
24-week group, were predominantly mild or moderate in
severity. The most common adverse events in both groups were
headache, insomnia, and fatigue (Table 3). Although some AEs
were more common in the 24-week group, this does not appear
to be the result simply of longer duration, since the differences
between the arms were observed during the ﬁrst 12 weeks of
treatment.
Serious adverse events were reported in three patients in the
sofosbuvir plus RBV 24-week group. One patient experienced
severe non-cardiac chest pain and a second patient had severe
abdominal pain during the dosing period. The third patient expe-
rienced transient loss of consciousness after a transatlantic ﬂightvol. 62 j 1040–1046 1043
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four days after completing treatment. All these adverse events
resolved and none was considered to be treatment related.
Consistent with changes in laboratory values typically associ-
ated with RBV, decreases from baseline in hemoglobin and
increases in reticulocytes and platelets were observed during
treatment. Four patients, all in the 24-week sofosbuvir plus
RBV group, had at least one hemoglobin level of <10 g/dl, but
none had hemoglobin <8.5 g/dl. Consistent with RBV-induced
hemolysis, one patient in each of the 12 and 24-week groups
had a total bilirubin value >2.5 times the upper limit of the refer-
ence range at week 1; values at subsequent visits decreased dur-
ing continued treatment. Serum glucose values >250 mg/dl
occurred in six patients in the 12-week sofosbuvir plus RBV
group and three patients in the 24-week group, all of whom
had concomitant diabetes.
Adverse events resulted in dose modiﬁcation or interruption
of RBV in two patients (6%) in the sofosbuvir plus RBV 12-week
group and 9 (31%) in the 24-week group. Moderate dyspnea led
to permanent discontinuation of RBV on day 36 of treatment in
a treatment-experienced patient in the 24-week group;Table 3. Adverse events.







Any AE 28 (90) 29 (100)
Serious AE 0 3 (10)
Severe 1 (3) 3 (10)
AE leading to discontinuation of 
study treatment
0 0*
AEs in at least 20% of patients in either treatment group
Headache 18 (58) 19 (66)
Insomnia 16 (52) 14 (48)
Fatigue 14 (45) 15 (52)
Cough 6 (19) 13 (45)
Irritability 6 (19) 10 (34)
Dizziness 5 (16) 9 (31)
Pruritus 7 (23) 7 (24)
Oropharyngeal pain 5 (16) 8 (28)
Dyspnea 5 (16) 7 (24)
Abdominal distension 4 (13) 6 (21)
Pain 4 (13) 6 (21)
Rash 1(3) 9 (31)
Myalgia 2 (6) 6 (21)
Nausea 2 (6) 6 (21)
Palpitations 2 (6) 6 (21)
Diarrhea 1 (3) 6 (21)
Laboratory abnormality
Hemoglobin
<10 g/dl 0 4 (14)
<8.5 g/dl 0 0
Platelets <50,000/mm3 0 0
ANC <750/mm3 1 (3) 0
Total bilirubin >2.5xULN 1 (3) 1 (3)
Glucose >250 mg/dl† 6 (19) 3 (10)
ANC, absolute neutrophil count; ULN, upper limit of normal.
⁄One subject discontinued RBV but continued SOF.
1044 Journal of Hepatology 2015sofosbuvir was continued for the remainder of the treatment
period and the patient achieved SVR24. No patients had adverse
events leading to dose modiﬁcation, interruption, or discontin-
uation of sofosbuvir.Discussion
In this phase 2, open-label study, 24 weeks of treatment with
sofosbuvir and RBV resulted in high rates of SVR12 in
treatment-naive and previously treated patients with genotype
4 HCV. SVR12 rates were notably high in patients with character-
istics historically associated with poor response-cirrhosis, high
baseline viral load, non-CC IL28B genotype, and prior
non-response to HCV treatment. The regimen was well tolerated,
with mostly mild adverse events typically associated with RBV
therapy. Overall, RBV dose modiﬁcation or interruption did not
appear to have an effect on SVR. No viable resistance-associated
variants were detected in any of the patients who did not achieve
SVR.
Overall and in nearly every patient subgroup, patients receiv-
ing 24 weeks of treatment had substantially higher rates of
SVR12 than patients receiving 12 weeks of treatment. In some
subgroups – e.g., males, cirrhotics, patients with genotype 4a
HCV – the difference was 30 percentage points or more.
Unsurprisingly, treatment-naive patients overall had higher rates
of SVR12 than did treatment-experienced patients, but among
treatment-naive patients, the SVR rate was 21 percentage points
higher among those receiving 24 weeks of treatment than those
receiving 12 weeks (Table 4). On the basis of these preliminary
data, the only subgroups for whom 12 weeks of this regimen
would appear to be adequate are patients with low baseline
HCV RNA levels and those with the CC IL28B genotype.
However, any such conclusions are necessarily preliminary given
the small numbers of patients in some subgroups.
The results in our 24-week arm compare favorably with other
recently approved regimens for which data are currently avail-
able in patients with genotype 4 HCV. In a phase 3 trial, the sec-
ond generation HCV NS3/4A protease inhibitor simeprevir was
administered for 12 weeks with PegIFNa and RBV followed by a
further 12–36 weeks of PegIFNa and RBV (depending on
on-treatment response) to 107 patients with genotype 4 HCV.
The overall rate of SVR12 was 65%, but the rate varied greatly
by treatment history: 83% in treatment-naive patients, 86% in pri-
or relapsers, 60% in prior partial responders, but only 40% in
patients with prior non-response [15]. Although results above
are comparable to our results in the 12-week arm for
treatment-naive and previous relapsers, treatment with sofosbu-
vir plus RBV appears to be better tolerated. Simeprevir adminis-
tered in combination with sofosbuvir is also approved in
Europe for the treatment of genotype 4 patients who are
interferon-intolerant or ineligible, but no data are presently avail-
able for this regimen in patients with genotype 4 HCV.
Other direct-acting antiviral agents have also been evaluated
in phase 2 studies in patients with genotype 4 HCV infection.
One such study evaluated 12 weeks of treatment with the pro-
tease inhibitor ABT-450 with ritonavir (ABT-450/r) and the
NS5A inhibitor ombitasvir, with or without RBV, in genotype 4
patients without cirrhosis [16]. In treatment-naive patients, the
RBV-containing regimen resulted in a 100% SVR12 rate
(n = 42/42), while the regimen without RBV resulted in a 91%
SVR12 rate (n = 40/44). The SVR12 rate has not yet been reportedvol. 62 j 1040–1046
Table 4. SVR12 rates by treatment experience and subgroups.
Patients, n/N (%; 95% CI) Treatment naïve Treatment experienced
SOF + RBV 12 week SOF + RBV 24 week SOF + RBV 12 week SOF + RBV 24 week
Overall 11/14 (79) 14/14 (100) 10/17 (59) 13/15 (87)
Age
<65 yr 10/13 (77%; 46-95) 9/9 (100%; 66-100) 9/14 (64%; 35-87) 11/11 (100%; 72-100)
≥65 yr 1/1 (100%; 3-100) 5/5 (100%; 48-100) 1/3 (33%; 1-91) 2/4 (50%; 7-93)
Sex
Men 6/8 (75%; 35-97) 5/5 (100%; 48-100) 7/14 (50%; 23-77) 12/14 (86%; 57-98)
Women 5/6 (83%; 36-100) 9/9 (100%; 66-100) 3/3 (100%; 29-100) 1/1 (100%; 3-100)
BMI
<30 kg/m2 7/9 (78%; 40-97) 7/7 (100%; 59-100) 8/14 (57%; 29-82) 8/10 (80%; 44-97)
≥30 kg/m2 4/5 (80%; 28-99) 7/7 (100%; 59-100) 2/3 (67%; 9-99) 5/5 (100%; 48-100)
Baseline HCV RNA
<800,000 IU/ml 6/7 (86%; 42-100) 8/8 (100%; 63-100) 4/4 (100%; 40-100) 6/7 (86%; 42-100)
≥800,000 IU/ml 5/7 (71%; 29-96) 6/6 (100%; 54-100) 6/13 (46%; 19-75) 7/8 (88%; 47-100)
Cirrhosis status
Yes 1/3 (33%; 1-91) 3/3 (100%; 29-100) 2/4 (50%; 7-93) 4/4 (100%; 40-100)
No 10/11 (91%; 59-100) 11/11 (100%; 72-100) 8/13 (62%; 32-86) 9/11 (82%; 48-98)
HCV genotype
4a 10/12 (83%; 52-98) 8/8 (100%; 63-100) 9/16 (56%; 30-80) 12/12 (100%; 74-100)
Other (4l, 4m, 4n, 4o) 1/2 (50%; 1-99) 6/6 (100%; 54-100) 1/1 (100%; 3-100) 1/3 (33%; 1-91)
IL28B genotype
CC 3/3 (100%; 29-100) 6/6 (100%; 54-100) 1/1 (100%; 3-100) 0
Non-CC 8/11 (73%; 39-94) 8/8 (100%; 63-100) 9/16 (56%;30-80) 13/15 (87%; 60-98)
CI, conﬁdence interval; GT, genotype; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir.
JOURNAL OF HEPATOLOGYfor the group of treatment-experienced patients (n = 49) who
received ABT-450/r plus ombitasvir plus RBV. In a small study,
a total of 21 treatment-naive genotype 4 patients were random-
ized to receive daclatasvir, a NS5A inhibitor, and asunaprevir, a
NS3 protease inhibitor, and one of two dose levels of
BMS-791325, a non-nucleoside NS5B polymerase inhibitor, for
12 weeks [17]. All 21 patients achieved SVR12, suggesting the
combination of these agents merits further evaluation. The safety
and efﬁcacy of sofosbuvir in combination with the NS5A inhibitor
ledipasvir in patients with genotype 4 is being evaluated in stud-
ies in Egypt and France.
There is a need in Egypt for an interferon-free regimen that is
well tolerated and provides a high degree of efﬁcacy for the treat-
ment of genotype 4 HCV infection. However, the results from this
study may have broader application. Although some studies have
found response rates with interferon plus RBV to be higher in
Egyptian patients than European patients with genotype 4 HCV
infection [18,19], other studies have not found a difference in
response based on ethnicity [20,21]. Differences in efﬁcacy have
been associated with differences in patient characteristics includ-
ing genotype 4a, which predominates in Egypt whereas in Europe
genotypes 4a and 4d are common and greater subtype diversity is
present in patients from Africa [20,22]. The IL28B CC genotype
has been associated with higher response rates to treatment with
interferon plus RBV in genotype 4 HCV infection [23] and, in turn,
a higher frequency of the C allele was found in Egyptian patients
relative to Europeans and Sub-Saharan Africans [23]. In this
study, 20% of patients had a subtype other than genotype 4a
and 83% had IL28B non-CC status. Regardless of genotype 4 sub-
type or IL28B status, sofosbuvir plus RBV administered for
24 weeks resulted in high SVR12 rates.Journal of Hepatology 2015Limitations of this study include the absence of complete prior
treatment histories in all patients, particularly those who had
previously been treated for HCV in Egypt, and the small number
of patients infected with non-4a HCV. The absence of data in
patients with other genotype 4 subtypes and other racial and eth-
nic groups does not permit us to speculate about the beneﬁt of
the regimen for these populations.
Effective interferon-free regimens are associated with impor-
tant advantages in treating chronic HCV, including sparing
patients the rigors and toxicity of protracted interferon therapy.
The increasing availability of such regimens has spurred calls
for stepped up screening for HCV in countries of high endemicity
[24]. The ﬁndings from the present study suggest that sofosbuvir
plus RBV may offer an efﬁcacious and well tolerated treatment in
patients with HCV genotype 4 infection, and one that may facil-
itate treatment of large numbers of Egyptian patients. A phase
3 trial of sofosbuvir plus RBV for 12 or 24 weeks in patients with
genotype 4 is ongoing in Egypt.Financial support
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